ClinicalTrials.gg
CompletedNCT07215806Updated Nov 14, 2025Results posted

Effect of Evobrutinib on Pharmacokinetics of a Combined Oral Contraceptive

A Phase 1 interventional study of Evobruitnib and Combined oral contraceptive [ethinyl estradiol/ norethisterone (EE/NET)] in Healthy, sponsored by Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany. Completed at 1 site in Germany. Open to female participants aged 18 Years to 68 Years. Per ClinicalTrials.gov, last updated 2025-11-14.

Sponsored by Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany (part of Merck KGaA, Darmstadt, Germany) · Phase 1, Interventional, and Other

From the registry’s dates

  • Registered 3 years 1 month after the study started (first participant enrolled Aug 2022, registered Oct 2025).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
18 Years to 68 Years
Sex
Female
01

Study summary

The purpose of this study was to assess the effect of M2951 on the pharmacokinetics (PK) of a combined oral contraceptive [Ethinyl estradiol/Norethisterone (EE/NET)] in healthy female participants.

  • Study Duration: up to 46 days
  • Treatment Duration: Days 4 to 17 (14 days treatment with M2951); Days 1 and 15 (2 days treatment with Combined Oral Contraceptive [COC])
  • Visit Frequency: Participants were resident in the Clinical Research Unit from Day -1 to Day 18.
02

Conditions studied

  • Healthy

Keywords

  • Drug-drug interaction
  • Clinical pharmacology
03

In context

Lead sponsor

Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany is the lead sponsor of 56 studies on the registry; 5 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 68 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants are overtly healthy as determined by medical evaluation, including no abnormality identified on physical examination or laboratory evaluation and no active clinically significant disorder, condition, infection or disease that would pose a risk to participant safety or interfere with the study evaluation, procedures, or completion
  • Participants have a body weight within 50.0 and 100.0 kilograms (kg) (inclusive) and within the range 19.0 and 30.0 kilograms per square meter (kg/m\^2) (inclusive)
  • Participants are nonsmokers for at least 6 months preceding Screening
  • Female participants who are not a Woman of (WOCBP)
  • Other protocol defined inclusion criteria could apply

Exclusion criteria

Exclusion Criteria:

  • Participants with history or presence of respiratory, gastrointestinal, renal, hepatic, hematological, lymphatic, neurological, cardiovascular, psychiatric, musculoskeletal, genitourinary, immunological, dermatological, connective tissue diseases or disorders, as determined by medical evaluation
  • Participants with diagnosis of hemochromatosis, Wilson´s disease, alpha 1 antitrypsin deficiency, or any other chronic liver disease including Gilbert's disease will be excluded from the study
  • Participants with prior history of splenectomy or any clinically relevant surgery within 3 months prior to Screening
  • Participants with history of any
  • Participants with history of chronic or recurrent acute infection or any bacterial, viral, parasitic, or fungal infections within 30 days prior to Screening and at any time between Screening and admission, or hospitalization due to infection within 6 months prior to Screening
  • Participants with history of shingles within 12 months prior to Screening
  • Administration of or live-attenuated virus vaccines within 3 months prior to Screening. Administration of other types of vaccines [e.g., Severe acute respiratory syndrome coronavirus 2 (SARSCoV2) vaccines] is allowed until 4 weeks before admission to CRU, thereafter it is prohibited until the end of the study
  • Note: In case of clinical symptoms, the participant should be symptom-free for at least 1 week prior to admission to Clinical Research Unit (CRU)
  • Other protocol defined exclusion criteria could apply
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (actual)

Study arms

  • Experimental
    COC + Evobrutinib

    Participants received combined oral contraceptive (COC) \[0.03 milligrams (mg) of Ethinyl Estradiol (EE)\], 0.5 mg of Norethisterone (NET)\] orally on Day 1 and 15 in combination with Evobruitnib at a dose of 45 mg orally twice daily on Days 4 to 17.

    Drug: Evobruitnib · Drug: Combined oral contraceptive [ethinyl estradiol/ norethisterone (EE/NET)]

Interventions

  • DrugEvobruitnib

    Participants received Evobruitnib at a dose of 45 mg orally twice daily on Days 4 to 17.

  • DrugCombined oral contraceptive [ethinyl estradiol/ norethisterone (EE/NET)]

    Drug page: Contraceptives, Oral, Combined

    Participants received combined oral contraceptive (COC) \[0.03 milligrams (mg) of Ethinyl Estradiol (EE)\], 0.5 mg of Norethisterone (NET)\] orally on Day 1 and 15.

06

What researchers measure

Primary outcomes

  1. Area Under the Plasma Concentration-time Curve From Time Zero Extrapolated to Infinity (AUC0-inf) of Ethinyl Estradiol and Norethisterone

    AUC0-inf was calculated by combining AUC0-t and AUCextra. AUCextra represents an extrapolated value obtained by Clast pred/Lambda z, where Clast pred was the calculated serum concentration at the last sampling time point at which the measured serum concentration is at or above the Lower Limit of quantification (LLOQ) and Lambda z was the apparent terminal rate constant determined by log-linear regression analysis of the measured serum concentrations of the terminal log-linear phase.

    Time frame: Pre-dose, 0.3, 0.6, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48, 60 and 72 hours post-dose on Days 1, 2, 3, 4, 15, 16, 17 and 18

  2. Maximum Observed Plasma Concentration (Cmax) of Ethinyl Estradiol and Norethisterone

    Cmax was obtained directly from the concentration versus time curve.

    Time frame: Pre-dose, 0.3, 0.6, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48, 60 and 72 hours post-dose on Days 1, 2, 3, 4, 15, 16, 17 and 18

Secondary outcomes

  1. Number of Participants With Treatment- Emergent Adverse Events (TEAEs)

    An adverse event (AE) is defined as any untoward medical occurrence in a participant or clinical study participant, temporally associated with the use of study intervention, whether considered related to the study intervention or not. A serious AE was an AE that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged inpatient hospitalization; congenital anomaly/birth defect or was otherwise considered medically important. TEAEs were defined as events with onset date or worsening during the on-treatment period. TEAEs included both serious and non-serious TEAEs.

    Time frame: Up to 46 days

  2. Number of Participants With Treatment- Emergent Adverse Events (TEAEs) by Severity

    The Investigator assessed the severity of each AE and SAE reported during the study and assign it to one of the following categories: Mild: An event that is easily tolerated by the participant, causing minimal discomfort and not interfering with everyday activities; Moderate: An event that causes sufficient discomfort and interferes with normal everyday activities; Severe: An event that prevents normal everyday activities. Do not confuse an AE that is assessed as severe with a SAE. Severe is a category used to rate the intensity of an event; both AEs and SAEs can be assessed as severe.

    Time frame: Up to 46 days

  3. Change From Baseline in Hematology Parameter: Hemoglobin at Day 18

    Blood samples were collected in a fasted condition (after a fast of at least 12 hours) to analyze the hematology parameter: hemoglobin.

    Time frame: Baseline, Day 18

  4. Change From Baseline in Hematology Parameter: Erythrocytes at Day 18

    Blood samples were collected in a fasted condition (after a fast of at least 12 hours) to analyze the hematology parameter: Erythrocytes.

    Time frame: Baseline, Day 18

  5. Change From Baseline in Hematology Parameters: Platelets, Leukocytes, Neutrophils, Eosinophils, Basophils, Monocytes and Lymphocytes at Day 18

    Blood samples were collected in a fasted condition (after a fast of at least 12 hours) to analyze the hematology parameters: Platelets, Leukocytes, Neutrophils, Eosinophils, Basophils, Monocytes and Lymphocytes.

    Time frame: Baseline, Day 18

  6. Change From Baseline in Hematology Parameters: Hematocrit, Basophils/Leukocytes, Eosinophils/Leukocytes, Lymphocytes/Leukocytes, Monocytes/Leukocytes and Neutrophils/Leukocytes at Day 18

    Blood samples were collected in a fasted condition (after a fast of at least 12 hours) to analyze the hematology parameters: Hematocrit, Basophils/Leukocytes, Eosinophils/Leukocytes, Lymphocytes/Leukocytes, Monocytes/Leukocytes and Neutrophils/Leukocytes.

    Time frame: Baseline, Day 18

  7. Change From Baseline in Coagulation Parameter: Activated Partial Thromboplastin Time at Day 18

    Blood samples were collected in a fasted condition (after a fast of at least 12 hours) to analyze the coagulation parameter: Activated Partial Thromboplastin Time.

    Time frame: Baseline, Day 18

  8. Change From Baseline in Hematology Parameter: Erythrocytes Mean Corpuscular Hemoglobin at Day 18

    Blood samples were collected in a fasted condition (after a fast of at least 12 hours) to analyze the hematology parameter: Erythrocytes Mean Corpuscular Hemoglobin.

    Time frame: Baseline, Day 18

  9. Change From Baseline in Hematology Parameter: Erythrocytes Mean Corpuscular Volume at Day 18

    Blood samples were collected in a fasted condition (after a fast of at least 12 hours) to analyze the hematology parameter: Erythrocytes Mean Corpuscular Volume.

    Time frame: Baseline, Day 18

  10. Change From Baseline in Coagulation Parameter: Prothrombin Intl. Normalized Ratio at Day 18

    Blood samples were collected in a fasted condition (after a fast of at least 12 hours) to analyze the coagulation parameter: Prothrombin Intl. Normalized Ratio.

    Time frame: Baseline, Day 18

  11. Change From Baseline in Chemistry Parameters: Bilirubin, Creatinine and Urate at Day 18

    Blood samples were collected in a fasted condition (after a fast of at least 12 hours) to analyze the chemistry parameter: bilirubin, creatinine and urate.

    Time frame: Baseline, Day 18

  12. Change From Baseline in Chemistry Parameters: Aspartate Aminotransferase, Alanine Aminotransferase, Alkaline Phosphatase, Amylase, Lipase, Gamma Glutamyl Transferase and Lactate Dehydrogenase at Day 18

    Blood samples were collected in a fasted condition (after a fast of at least 12 hours) to analyze the chemistry parameter: Aspartate Aminotransferase, Alanine Aminotransferase, Alkaline Phosphatase, Amylase, Lipase, Gamma Glutamyl Transferase and Lactate Dehydrogenase.

    Time frame: Baseline, Day 18

  13. Change From Baseline in Chemistry Parameters: Sodium, Potassium, Calcium, Glucose, Chloride and Triglycerides at Day 18

    Blood samples were collected in a fasted condition (after a fast of at least 12 hours) to analyze the chemistry parameter: Sodium, Potassium, Calcium, Glucose, Chloride and Triglycerides.

    Time frame: Baseline, Day 18

  14. Change From Baseline in Chemistry Parameters: Total Protein at Day 18

    Blood samples were collected in a fasted condition (after a fast of at least 12 hours) to analyze the chemistry parameter: Total Protein.

    Time frame: Baseline, Day 18

  15. Change From Baseline in Chemistry Parameters: C Reactive Protein at Day 18

    Blood samples were collected in a fasted condition (after a fast of at least 12 hours) to analyze the chemistry parameter: C Reactive Protein.

    Time frame: Baseline, Day 18

  16. Change From Baseline in Vital Signs: Systolic Blood Pressure and Diastolic Blood Pressure at Day 18

    Diastolic blood pressure and systolic blood pressure were measured after at least 5 minutes of rest for the participant in a quiet sitting without distractions.

    Time frame: Baseline, Day 18

  17. Change From Baseline in Vital Signs: Pulse Rate at Day 18

    Pulse rate was measured after at least 5 minutes of rest for the participant in a quiet sitting without distractions.

    Time frame: Baseline, Day 18

  18. Change From Baseline in Vital Signs: Respiratory Rate at Day 18

    Respiratory rate was measured after at least 5 minutes of rest for the participant in a quiet sitting without distractions.

    Time frame: Baseline, Day 18

  19. Change From Baseline in Vital Signs: Temperature at Day 18

    Temperature was measured after at least 5 minutes of rest for the participant in a quiet sitting without distractions.

    Time frame: Baseline, Day 18

  20. Change From Baseline in Electrocardiograms (ECGs) Parameter: Heart Rate at Day 18

    Heart rate was measured after at least 5 minutes of rest for the participant in a quiet sitting without distractions

    Time frame: Baseline, Day 18

  21. Change From Baseline in Electrocardiograms (ECGs) Parameter: RR Duration, QT Duration, QTcF Duration, PR Duration, QRS Duration at Day 18

    RR Duration, QT Duration, QTcF Duration, PR Duration, QRS Duration was measured after at least 5 minutes of rest for the participant in a quiet sitting without distractions.

    Time frame: Baseline, Day 18

  22. Time to Reach Maximum Observed Plasma Concentration (Tmax) of Ethinyl Estradiol and Norethisterone

    Time to reach the maximum observed plasma concentration (Tmax) was obtained directly from the concentration versus time curve.

    Time frame: Pre-dose, 0.3, 0.6, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48, 60 and 72 hours post-dose on Days 1, 2, 3, 4, 15, 16, 17 and 18

  23. Terminal Half Life (T1/2) of Ethinyl Estradiol and Norethisterone

    Terminal half-life was calculated as log2 divided by lambda z. Lambda z was terminal elimination rate constant determined from the terminal slope of the log-transformed plasma concentration curve.

    Time frame: Pre-dose, 0.3, 0.6, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48, 60 and 72 hours post-dose on Days 1, 2, 3, 4, 15, 16, 17 and 18

  24. Area Under the Plasma Concentration Time Curve From Time Zero to the Time of the Last Quantifiable Concentration (AUC0-t) of Ethinyl Estradiol and Norethisterone

    The AUC from time zero (= dosing time) to the last sampling time (tlast) at which the concentration is at or above the lower limit of quantification (LLOQ). Calculated using the mixed log-linear trapezoidal rule (linear up, log down).

    Time frame: Pre-dose, 0.3, 0.6, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48, 60 and 72 hours post-dose on Days 1, 2, 3, 4, 15, 16, 17 and 18

  25. Apparent Total Body Clearance (CL/f) of Ethinyl Estradiol and Norethisterone

    Apparent total body clearance of drug from plasma following extravascular administration, calculated as dose/AUC0-infinity for Ethinyl Estradiol/Norethisterone.

    Time frame: Pre-dose, 0.3, 0.6, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48, 60 and 72 hours post-dose on Days 1, 2, 3, 4, 15, 16, 17 and 18

  26. Apparent Volume of Distribution During Terminal Phase (VZ/f) of Ethinyl Estradiol and Norethisterone

    Vz/f is defined as the apparent volume of distribution during the terminal phase following extravascular administration for Ethinyl Estradiol/Norethisterone.

    Time frame: Pre-dose, 0.3, 0.6, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48, 60 and 72 hours post-dose on Days 1, 2, 3, 4, 15, 16, 17 and 18

07

Results

Posted Nov 14, 2025

Participant flow

Participant flow — Overall Study
MilestoneCOC + Evobrutinib
Started20
Completed20
Not completed0

Outcome measures

PrimaryArea Under the Plasma Concentration-time Curve From Time Zero Extrapolated to Infinity (AUC0-inf) of Ethinyl Estradiol and Norethisterone

AUC0-inf was calculated by combining AUC0-t and AUCextra. AUCextra represents an extrapolated value obtained by Clast pred/Lambda z, where Clast pred was the calculated serum concentration at the last sampling time point at which the measured serum concentration is at or above the Lower Limit of quantification (LLOQ) and Lambda z was the apparent terminal rate constant determined by log-linear regression analysis of the measured serum concentrations of the terminal log-linear phase.

Time frame:
Pre-dose, 0.3, 0.6, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48, 60 and 72 hours post-dose on Days 1, 2, 3, 4, 15, 16, 17 and 18
Reported as:
Geometric mean · hour × picogram per milliliter (h×pg/mL)
Area Under the Plasma Concentration-time Curve From Time Zero Extrapolated to Infinity (AUC0-inf) of Ethinyl Estradiol and Norethisterone
hour × picogram per milliliter (h×pg/mL)COC + Evobrutinib
Ethinyl Estradiol1090 ± 26.7
Norethisterone36000 ± 35.9
PrimaryMaximum Observed Plasma Concentration (Cmax) of Ethinyl Estradiol and Norethisterone

Cmax was obtained directly from the concentration versus time curve.

Time frame:
Pre-dose, 0.3, 0.6, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48, 60 and 72 hours post-dose on Days 1, 2, 3, 4, 15, 16, 17 and 18
Reported as:
Geometric mean · pg/mL
Maximum Observed Plasma Concentration (Cmax) of Ethinyl Estradiol and Norethisterone
pg/mLCOC + Evobrutinib
Ethinyl Estradiol51.8 ± 30.1
Norethisterone4620 ± 34.0
SecondaryNumber of Participants With Treatment- Emergent Adverse Events (TEAEs)

An adverse event (AE) is defined as any untoward medical occurrence in a participant or clinical study participant, temporally associated with the use of study intervention, whether considered related to the study intervention or not. A serious AE was an AE that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged inpatient hospitalization; congenital anomaly/birth defect or was otherwise considered medically important. TEAEs were defined as events with onset date or worsening during the on-treatment period. TEAEs included both serious and non-serious TEAEs.

Time frame:
Up to 46 days
Reported as:
Count of participants · Participants
Number of Participants With Treatment- Emergent Adverse Events (TEAEs)
ParticipantsCOC + Evobrutinib
Number of Participants With Treatment- Emergent Adverse Events (TEAEs)9
SecondaryNumber of Participants With Treatment- Emergent Adverse Events (TEAEs) by Severity

The Investigator assessed the severity of each AE and SAE reported during the study and assign it to one of the following categories: Mild: An event that is easily tolerated by the participant, causing minimal discomfort and not interfering with everyday activities; Moderate: An event that causes sufficient discomfort and interferes with normal everyday activities; Severe: An event that prevents normal everyday activities. Do not confuse an AE that is assessed as severe with a SAE. Severe is a category used to rate the intensity of an event; both AEs and SAEs can be assessed as severe.

Time frame:
Up to 46 days
Reported as:
Count of participants · Participants
Number of Participants With Treatment- Emergent Adverse Events (TEAEs) by Severity
ParticipantsCOC + Evobrutinib
Mild8
Moderate1
Severe0
SecondaryChange From Baseline in Hematology Parameter: Hemoglobin at Day 18

Blood samples were collected in a fasted condition (after a fast of at least 12 hours) to analyze the hematology parameter: hemoglobin.

Time frame:
Baseline, Day 18
Reported as:
Mean · gram per liter (g/L)
Change From Baseline in Hematology Parameter: Hemoglobin at Day 18
gram per liter (g/L)COC + Evobrutinib
Change From Baseline in Hematology Parameter: Hemoglobin at Day 18-8.780 ± 7.7256
SecondaryChange From Baseline in Hematology Parameter: Erythrocytes at Day 18

Blood samples were collected in a fasted condition (after a fast of at least 12 hours) to analyze the hematology parameter: Erythrocytes.

Time frame:
Baseline, Day 18
Reported as:
Mean · 10^12 cells per liter
Change From Baseline in Hematology Parameter: Erythrocytes at Day 18
10^12 cells per literCOC + Evobrutinib
Change From Baseline in Hematology Parameter: Erythrocytes at Day 18-0.29 ± 0.263
SecondaryChange From Baseline in Hematology Parameters: Platelets, Leukocytes, Neutrophils, Eosinophils, Basophils, Monocytes and Lymphocytes at Day 18

Blood samples were collected in a fasted condition (after a fast of at least 12 hours) to analyze the hematology parameters: Platelets, Leukocytes, Neutrophils, Eosinophils, Basophils, Monocytes and Lymphocytes.

Time frame:
Baseline, Day 18
Reported as:
Mean · 10^9 cells per liter
Change From Baseline in Hematology Parameters: Platelets, Leukocytes, Neutrophils, Eosinophils, Basophils, Monocytes and Lymphocytes at Day 18
10^9 cells per literCOC + Evobrutinib
Platelets-18 ± 38.0
Leukocytes-0.08 ± 1.395
Neutrophils-0.21 ± 1.390
Eosinophils-0.00 ± 0.050
Basophils0.00 ± 0.017
Monocytes-0.02 ± 0.110
Lymphocytes0.16 ± 0.338
SecondaryChange From Baseline in Hematology Parameters: Hematocrit, Basophils/Leukocytes, Eosinophils/Leukocytes, Lymphocytes/Leukocytes, Monocytes/Leukocytes and Neutrophils/Leukocytes at Day 18

Blood samples were collected in a fasted condition (after a fast of at least 12 hours) to analyze the hematology parameters: Hematocrit, Basophils/Leukocytes, Eosinophils/Leukocytes, Lymphocytes/Leukocytes, Monocytes/Leukocytes and Neutrophils/Leukocytes.

Time frame:
Baseline, Day 18
Reported as:
Mean · percentage of cells
Change From Baseline in Hematology Parameters: Hematocrit, Basophils/Leukocytes, Eosinophils/Leukocytes, Lymphocytes/Leukocytes, Monocytes/Leukocytes and Neutrophils/Leukocytes at Day 18
percentage of cellsCOC + Evobrutinib
Hematocrit-0.029 ± 0.0227
Basophils/Leukocytes0.0 ± 0.30
Eosinophils/Leukocytes0.0 ± 0.63
Lymphocytes/Leukocytes3.2 ± 8.44
Monocytes/Leukocytes-0.2 ± 1.34
Neutrophils/Leukocytes-3.0 ± 9.30
SecondaryChange From Baseline in Coagulation Parameter: Activated Partial Thromboplastin Time at Day 18

Blood samples were collected in a fasted condition (after a fast of at least 12 hours) to analyze the coagulation parameter: Activated Partial Thromboplastin Time.

Time frame:
Baseline, Day 18
Reported as:
Mean · seconds
Change From Baseline in Coagulation Parameter: Activated Partial Thromboplastin Time at Day 18
secondsCOC + Evobrutinib
Change From Baseline in Coagulation Parameter: Activated Partial Thromboplastin Time at Day 18-1.6 ± 0.84
SecondaryChange From Baseline in Hematology Parameter: Erythrocytes Mean Corpuscular Hemoglobin at Day 18

Blood samples were collected in a fasted condition (after a fast of at least 12 hours) to analyze the hematology parameter: Erythrocytes Mean Corpuscular Hemoglobin.

Time frame:
Baseline, Day 18
Reported as:
Mean · picogram
Change From Baseline in Hematology Parameter: Erythrocytes Mean Corpuscular Hemoglobin at Day 18
picogramCOC + Evobrutinib
Change From Baseline in Hematology Parameter: Erythrocytes Mean Corpuscular Hemoglobin at Day 18-0.06283 ± 0.541316
SecondaryChange From Baseline in Hematology Parameter: Erythrocytes Mean Corpuscular Volume at Day 18

Blood samples were collected in a fasted condition (after a fast of at least 12 hours) to analyze the hematology parameter: Erythrocytes Mean Corpuscular Volume.

Time frame:
Baseline, Day 18
Reported as:
Mean · femtoliters
Change From Baseline in Hematology Parameter: Erythrocytes Mean Corpuscular Volume at Day 18
femtolitersCOC + Evobrutinib
Change From Baseline in Hematology Parameter: Erythrocytes Mean Corpuscular Volume at Day 18-0.7 ± 0.95
SecondaryChange From Baseline in Coagulation Parameter: Prothrombin Intl. Normalized Ratio at Day 18

Blood samples were collected in a fasted condition (after a fast of at least 12 hours) to analyze the coagulation parameter: Prothrombin Intl. Normalized Ratio.

Time frame:
Baseline, Day 18
Reported as:
Mean · ratio
Change From Baseline in Coagulation Parameter: Prothrombin Intl. Normalized Ratio at Day 18
ratioCOC + Evobrutinib
Change From Baseline in Coagulation Parameter: Prothrombin Intl. Normalized Ratio at Day 18-0.02 ± 0.042
SecondaryChange From Baseline in Chemistry Parameters: Bilirubin, Creatinine and Urate at Day 18

Blood samples were collected in a fasted condition (after a fast of at least 12 hours) to analyze the chemistry parameter: bilirubin, creatinine and urate.

Time frame:
Baseline, Day 18
Reported as:
Mean · micromole per liter (mcmol/L)
Change From Baseline in Chemistry Parameters: Bilirubin, Creatinine and Urate at Day 18
micromole per liter (mcmol/L)COC + Evobrutinib
Bilirubin-0.8 ± 3.11
Creatinine-4 ± 6.2
Urate4.1 ± 31.48
SecondaryChange From Baseline in Chemistry Parameters: Aspartate Aminotransferase, Alanine Aminotransferase, Alkaline Phosphatase, Amylase, Lipase, Gamma Glutamyl Transferase and Lactate Dehydrogenase at Day 18

Blood samples were collected in a fasted condition (after a fast of at least 12 hours) to analyze the chemistry parameter: Aspartate Aminotransferase, Alanine Aminotransferase, Alkaline Phosphatase, Amylase, Lipase, Gamma Glutamyl Transferase and Lactate Dehydrogenase.

Time frame:
Baseline, Day 18
Reported as:
Mean · units per liter (U/L)
Change From Baseline in Chemistry Parameters: Aspartate Aminotransferase, Alanine Aminotransferase, Alkaline Phosphatase, Amylase, Lipase, Gamma Glutamyl Transferase and Lactate Dehydrogenase at Day 18
units per liter (U/L)COC + Evobrutinib
Aspartate Aminotransferase-2 ± 6.2
Alanine Aminotransferase3 ± 11.8
Alkaline Phosphatase-4 ± 10.1
Amylase-1 ± 7.5
Lipase-2.0 ± 7.77
Gamma Glutamyl Transferase0 ± 5.4
Lactate Dehydrogenase-35 ± 19.7
SecondaryChange From Baseline in Chemistry Parameters: Sodium, Potassium, Calcium, Glucose, Chloride and Triglycerides at Day 18

Blood samples were collected in a fasted condition (after a fast of at least 12 hours) to analyze the chemistry parameter: Sodium, Potassium, Calcium, Glucose, Chloride and Triglycerides.

Time frame:
Baseline, Day 18
Reported as:
Mean · millimoles per liter (mmol/L)
Change From Baseline in Chemistry Parameters: Sodium, Potassium, Calcium, Glucose, Chloride and Triglycerides at Day 18
millimoles per liter (mmol/L)COC + Evobrutinib
Sodium1 ± 2.6
Potassium-0.03 ± 0.397
Calcium-0.04 ± 0.077
Glucose-0.10 ± 0.385
Chloride2 ± 2.4
Triglycerides0.2 ± 0.29
SecondaryChange From Baseline in Chemistry Parameters: Total Protein at Day 18

Blood samples were collected in a fasted condition (after a fast of at least 12 hours) to analyze the chemistry parameter: Total Protein.

Time frame:
Baseline, Day 18
Reported as:
Mean · gram per liter (g/L)
Change From Baseline in Chemistry Parameters: Total Protein at Day 18
gram per liter (g/L)COC + Evobrutinib
Change From Baseline in Chemistry Parameters: Total Protein at Day 18-2 ± 3.5
SecondaryChange From Baseline in Chemistry Parameters: C Reactive Protein at Day 18

Blood samples were collected in a fasted condition (after a fast of at least 12 hours) to analyze the chemistry parameter: C Reactive Protein.

Time frame:
Baseline, Day 18
Reported as:
Mean · milligram per liter (g/L)
Change From Baseline in Chemistry Parameters: C Reactive Protein at Day 18
milligram per liter (g/L)COC + Evobrutinib
Change From Baseline in Chemistry Parameters: C Reactive Protein at Day 184 ± 8.2
SecondaryChange From Baseline in Vital Signs: Systolic Blood Pressure and Diastolic Blood Pressure at Day 18

Diastolic blood pressure and systolic blood pressure were measured after at least 5 minutes of rest for the participant in a quiet sitting without distractions.

Time frame:
Baseline, Day 18
Reported as:
Mean · millimeters of mercury (mmHg)
Change From Baseline in Vital Signs: Systolic Blood Pressure and Diastolic Blood Pressure at Day 18
millimeters of mercury (mmHg)COC + Evobrutinib
Systolic Blood Pressure4 ± 12.5
Diastolic Blood Pressure3 ± 9.7
SecondaryChange From Baseline in Vital Signs: Pulse Rate at Day 18

Pulse rate was measured after at least 5 minutes of rest for the participant in a quiet sitting without distractions.

Time frame:
Baseline, Day 18
Reported as:
Mean · beats per minute
Change From Baseline in Vital Signs: Pulse Rate at Day 18
beats per minuteCOC + Evobrutinib
Change From Baseline in Vital Signs: Pulse Rate at Day 184 ± 10.6
SecondaryChange From Baseline in Vital Signs: Respiratory Rate at Day 18

Respiratory rate was measured after at least 5 minutes of rest for the participant in a quiet sitting without distractions.

Time frame:
Baseline, Day 18
Reported as:
Mean · breaths per minute
Change From Baseline in Vital Signs: Respiratory Rate at Day 18
breaths per minuteCOC + Evobrutinib
Change From Baseline in Vital Signs: Respiratory Rate at Day 180 ± 1.5
SecondaryChange From Baseline in Vital Signs: Temperature at Day 18

Temperature was measured after at least 5 minutes of rest for the participant in a quiet sitting without distractions.

Time frame:
Baseline, Day 18
Reported as:
Mean · degree Celsius
Change From Baseline in Vital Signs: Temperature at Day 18
degree CelsiusCOC + Evobrutinib
Change From Baseline in Vital Signs: Temperature at Day 180.2 ± 0.49
SecondaryChange From Baseline in Electrocardiograms (ECGs) Parameter: Heart Rate at Day 18

Heart rate was measured after at least 5 minutes of rest for the participant in a quiet sitting without distractions

Time frame:
Baseline, Day 18
Reported as:
Mean · beats per minute
Change From Baseline in Electrocardiograms (ECGs) Parameter: Heart Rate at Day 18
beats per minuteCOC + Evobrutinib
Change From Baseline in Electrocardiograms (ECGs) Parameter: Heart Rate at Day 18-4 ± 7.5
SecondaryChange From Baseline in Electrocardiograms (ECGs) Parameter: RR Duration, QT Duration, QTcF Duration, PR Duration, QRS Duration at Day 18

RR Duration, QT Duration, QTcF Duration, PR Duration, QRS Duration was measured after at least 5 minutes of rest for the participant in a quiet sitting without distractions.

Time frame:
Baseline, Day 18
Reported as:
Mean · milliseconds (msec)
Change From Baseline in Electrocardiograms (ECGs) Parameter: RR Duration, QT Duration, QTcF Duration, PR Duration, QRS Duration at Day 18
milliseconds (msec)COC + Evobrutinib
RR Duration51 ± 98.4
QT Duration3 ± 17.8
QTcF Duration-5 ± 11.0
PR Duration3 ± 15.3
QRS Duration-2 ± 9.6
SecondaryTime to Reach Maximum Observed Plasma Concentration (Tmax) of Ethinyl Estradiol and Norethisterone

Time to reach the maximum observed plasma concentration (Tmax) was obtained directly from the concentration versus time curve.

Time frame:
Pre-dose, 0.3, 0.6, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48, 60 and 72 hours post-dose on Days 1, 2, 3, 4, 15, 16, 17 and 18
Reported as:
Median · hours
Time to Reach Maximum Observed Plasma Concentration (Tmax) of Ethinyl Estradiol and Norethisterone
hoursCOC + Evobrutinib
Ethinyl Estradiol3.00 (1.50 to 6.02)
Norethisterone2.00 (0.667 to 3.00)
SecondaryTerminal Half Life (T1/2) of Ethinyl Estradiol and Norethisterone

Terminal half-life was calculated as log2 divided by lambda z. Lambda z was terminal elimination rate constant determined from the terminal slope of the log-transformed plasma concentration curve.

Time frame:
Pre-dose, 0.3, 0.6, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48, 60 and 72 hours post-dose on Days 1, 2, 3, 4, 15, 16, 17 and 18
Reported as:
Median · hours
Terminal Half Life (T1/2) of Ethinyl Estradiol and Norethisterone
hoursCOC + Evobrutinib
Ethinyl Estradiol21.5 (10.5 to 32.1)
Norethisterone12.7 (7.58 to 20.9)
SecondaryArea Under the Plasma Concentration Time Curve From Time Zero to the Time of the Last Quantifiable Concentration (AUC0-t) of Ethinyl Estradiol and Norethisterone

The AUC from time zero (= dosing time) to the last sampling time (tlast) at which the concentration is at or above the lower limit of quantification (LLOQ). Calculated using the mixed log-linear trapezoidal rule (linear up, log down).

Time frame:
Pre-dose, 0.3, 0.6, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48, 60 and 72 hours post-dose on Days 1, 2, 3, 4, 15, 16, 17 and 18
Reported as:
Geometric mean · h×pg/mL
Area Under the Plasma Concentration Time Curve From Time Zero to the Time of the Last Quantifiable Concentration (AUC0-t) of Ethinyl Estradiol and Norethisterone
h×pg/mLCOC + Evobrutinib
Ethinyl Estradiol964 ± 26.9
Norethisterone35100 ± 36.4
SecondaryApparent Total Body Clearance (CL/f) of Ethinyl Estradiol and Norethisterone

Apparent total body clearance of drug from plasma following extravascular administration, calculated as dose/AUC0-infinity for Ethinyl Estradiol/Norethisterone.

Time frame:
Pre-dose, 0.3, 0.6, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48, 60 and 72 hours post-dose on Days 1, 2, 3, 4, 15, 16, 17 and 18
Reported as:
Geometric mean · Liter per hour
Apparent Total Body Clearance (CL/f) of Ethinyl Estradiol and Norethisterone
Liter per hourCOC + Evobrutinib
Ethinyl Estradiol27.6 ± 26.7
Norethisterone13.9 ± 35.9
SecondaryApparent Volume of Distribution During Terminal Phase (VZ/f) of Ethinyl Estradiol and Norethisterone

Vz/f is defined as the apparent volume of distribution during the terminal phase following extravascular administration for Ethinyl Estradiol/Norethisterone.

Time frame:
Pre-dose, 0.3, 0.6, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48, 60 and 72 hours post-dose on Days 1, 2, 3, 4, 15, 16, 17 and 18
Reported as:
Geometric mean · Liter
Apparent Volume of Distribution During Terminal Phase (VZ/f) of Ethinyl Estradiol and Norethisterone
LiterCOC + Evobrutinib
Ethinyl Estradiol816 ± 26.0
Norethisterone252 ± 46.7

Adverse events

Collected over Up to 46 days. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
COC + Evobrutinib0/20 (0%)0/20 (0%)9/20 (45%)
Most frequent other events
Showing 10 of 14
Most frequent other events
EventCOC + Evobrutinib
PollakiuriaRenal and urinary disorders6/20
Abnormal faecesGastrointestinal disorders1/20
Defaecation urgencyGastrointestinal disorders1/20
FlatulenceGastrointestinal disorders1/20
Gastrointestinal disorderGastrointestinal disorders1/20
FatigueGeneral disorders1/20
NasopharyngitisInfections and infestations1/20
ArthralgiaMusculoskeletal and connective tissue disorders1/20
Pain in extremityMusculoskeletal and connective tissue disorders1/20
HeadacheNervous system disorders1/20

Baseline characteristics

Age, Continuous
Age, Continuous(Years)COC + Evobrutinib
Mean57 ± 6.8
Sex: Female, Male
Sex: Female, Male(Participants)COC + Evobrutinib
Female20
Male0
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)COC + Evobrutinib
Hispanic or Latino0
Not Hispanic or Latino20
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)COC + Evobrutinib
American Indian or Alaska Native0
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American0
White20
More than one race0
Unknown or Not Reported0
08

Study locations

1 site
  • Nuvisan GmbH
    Neu-Ulm, Germany
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — We are committed to enhancing public health through responsible sharing of clinical trial data. Following approval of a new product or a new indication for an approved product in both the US and the European Union, the study sponsor and/or its affiliated companies will share study protocols, anonymized patient data and study level data, and redacted clinical study reports with qualified scientific and medical researchers, upon request, as necessary for conducting legitimate research. Further information on how to request data can be found on our website http://bit.ly/IPD21

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2022 to primary completion in Nov 2022, 3 months.

Results were first posted in Nov 2025, 2 years 11 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 8, 2025
First posted
Oct 14, 2025
StartActual
Aug 24, 2022
Primary completionActual
Nov 25, 2022
CompletionActual
Nov 25, 2022
Results first posted
Nov 14, 2025
Last update
Nov 14, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 14, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT07215806
Responsible party
Sponsor
First posted
Oct 14, 2025
Start date
Aug 24, 2022
Primary completion
Nov 25, 2022
Completion
Nov 25, 2022
Results posted
Nov 14, 2025
Last update
Nov 14, 2025

Study contacts

Medical Responsible
study director · Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Contraceptives, Oral, Combined

Start the discussion